Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors

This article was originally published in PharmAsia News

Executive Summary

Pfizer management, more bullish than the Street on long-term revenue forecasts for the combination of Pfizer and Wyeth, assured investors that incremental growth opportunities will emerge from the mega merger during a follow-up meeting with investors Jan. 27

You may also be interested in...



Japanese Pharmas Investing Heavily in Emerging Markets - BioJapan Conference

By 2030 the total pharma market size of BRIC countries, together with Mexico and Turkey, could reach $330 billion to $420 billion - almost equal to the combined market size of North America and Japan in 2006, which was $354 billion..

Japanese Pharmas Investing Heavily in Emerging Markets - BioJapan Conference

By 2030 the total pharma market size of BRIC countries, together with Mexico and Turkey, could reach $330 billion to $420 billion - almost equal to the combined market size of North America and Japan in 2006, which was $354 billion..

Pfizer To Become Largest Pharma In Japan After Wyeth Merger

TOKYO - Pfizer Japan says upon Pfizer's expected merger with Wyeth later this year, it will become the largest pharmaceutical company in Japan, surpassing Takeda Pharmaceutical

Related Content

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel